In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks involves focusing on companies that demonstrate robust innovation and adaptability in response to evolving market dynamics.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 20.44% | 29.79% | ★★★★★★ |
| TG Therapeutics | 26.18% | 37.61% | ★★★★★★ |
| Alkami Technology | 20.46% | 85.16% | ★★★★★★ |
| Travere Therapeutics | 28.43% | 65.01% | ★★★★★★ |
| Clene | 60.86% | 63.07% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.76% | 58.56% | ★★★★★★ |
| AVITA Medical | 27.91% | 55.77% | ★★★★★★ |
| TKO Group Holdings | 22.48% | 25.17% | ★★★★★★ |
| Lumentum Holdings | 21.55% | 119.67% | ★★★★★★ |
| Ascendis Pharma | 32.36% | 59.79% | ★★★★★★ |
Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Chimerix (NasdaqGM:CMRX)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Chimerix, Inc. is a biopharmaceutical company focused on developing medicines to enhance and prolong the lives of patients with life-threatening diseases, with a market cap of approximately $797.33 million.
Operations: Chimerix generates revenue primarily from its pharmaceuticals segment, which contributed $0.21 million.
Chimerix, despite its modest revenue of $212K, is on a trajectory with a forecasted annual revenue growth rate of 52.8%, significantly outpacing the US market's 8.3%. The company's recent earnings report revealed a jump in quarterly revenue to $0.057 million from $0.004 million year-over-year, although it still posted a substantial net loss of $22.95 million. Notably, Chimerix is poised for transformation through an impending acquisition by Jazz Pharmaceuticals for approximately $930 million, promising substantial cash per share to stakeholders and potentially stabilizing its financial footing as it moves towards profitability projected within three years.
- Navigate through the intricacies of Chimerix with our comprehensive health report here.
Review our historical performance report to gain insights into Chimerix's's past performance.
Apellis Pharmaceuticals (NasdaqGS:APLS)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutic compounds for diseases with high unmet needs, with a market cap of approximately $3.05 billion.
Operations: Apellis Pharmaceuticals focuses on developing and commercializing proprietary therapeutics, generating approximately $781.37 million in revenue from these activities.
Apellis Pharmaceuticals has demonstrated a robust turnaround in its financial performance, with a significant reduction in net loss to $36.35 million from $88.58 million year-over-year and an impressive revenue increase to $212.53 million from $146.38 million in the same period. This growth trajectory is underpinned by strategic R&D investments, which are pivotal as the company advances novel treatments like SYFOVRE for geographic atrophy—a market with high unmet medical needs. Moreover, the successful progression of their VALIANT study for rare kidney diseases represents potential future revenue streams, reinforcing Apellis's commitment to addressing complex health challenges through innovation.
- Get an in-depth perspective on Apellis Pharmaceuticals' performance by reading our health report here.
Assess Apellis Pharmaceuticals' past performance with our detailed historical performance reports.
Enfusion (NYSE:ENFN)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Enfusion, Inc. offers software-as-a-service solutions tailored for the investment management industry across various regions including the United States, Europe, the Middle East, Africa, and the Asia Pacific with a market capitalization of $1.43 billion.
Operations: Enfusion generates revenue primarily from its online financial information services, amounting to $201.61 million. The company operates in multiple regions, focusing on providing software solutions for the investment management sector.
Amidst a dynamic tech landscape, Enfusion stands out with its robust annual earnings growth forecast at 62.7%, significantly outpacing the US market average of 13.8%. This growth is underlined by a strong R&D commitment, which has seen a substantial allocation of resources, reflecting in their latest R&D expense figures. The company's recent merger announcement with Clearwater Analytics underscores its strategic expansion efforts and could potentially enhance its market position through synergies and expanded offerings. Despite facing challenges like a revenue growth (14.7%) that trails the high-growth benchmark of 20%, Enfusion’s innovative approach and recent strategic moves suggest it remains a noteworthy entity in the tech sector, poised for future opportunities post-merger integration completion expected in Q2 2025.
- Click here and access our complete health analysis report to understand the dynamics of Enfusion.
Evaluate Enfusion's historical performance by accessing our past performance report.
Key Takeaways
- Discover the full array of 234 US High Growth Tech and AI Stocks right here.
- Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
- Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Chimerix might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com